OXALIPLATIN INJECTION, USP 5 MG — DIN 02458403
OXALIPLATIN : 5 MG · DR REDDY'S LABORATORIES LTD · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is OXALIPLATIN INJECTION, USP?
OXALIPLATIN INJECTION, USP 5 MG contains OXALIPLATIN : 5 MG. It is listed in the Health Canada Drug Product Database under DIN 02458403, held by DR REDDY'S LABORATORIES LTD, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 13-Jul-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OXALIPLATIN INJECTION, USP used for?
Oxaliplatin Injection, USP, in combination with infusional 5-fluorouracil/leucovorin (5-FU/LV) is indicated for: Adjuvant treatment of patients with stage III (Dukes' C) colon cancer after complete resection of primary tumor. Treatment of patients with metastatic colorectal cancer.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Oxaliplatin cost around the world?
Oxaliplatin is listed on 10 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Bahrain publishes a retail (max); Czechia publishes a max producer price (ex-factory). Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| Saudi Arabia | public | 18 | 26 | SAR███.██ |
| South Africa | single exit price | 22 | 22 | ZAR███.██ |
| Czechia | max producer price (ex-factory) | 5 | 11 | CZK███.██ |
| United Arab Emirates | public | 6 | 8 | AED███.██ |
| Greece | producer price (ex-factory) | 7 | 7 | EUR███.██ |
| Romania | max producer price | 2 | 6 | RON███.██ |
| Australia | ex-manufacturer | 2 | 4 | AUD███.██ |
| United Kingdom | hospital | 3 | 3 | GBP███.██ |
| Lebanon | public price (USD, Decision 119/1) | 1 | 2 | USD███.██ |
| Bahrain | retail (max) | 1 | 1 | BHD███.██ |
90 pack listings across 67 brand entries and 9 price bases, refreshed 08 Sep 2026. Ranges span every Oxaliplatin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Oxaliplatin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
15 holders have a Canadian DIN containing Oxaliplatin, across 22 DINs, of which 5 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| TEVA CANADA LIMITED | 2 | 1 | OXALIPLATIN INJECTION, TEVA-OXALIPLATIN INJECTION | Sourceable in Canada |
| DR REDDY'S LABORATORIES LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 1 | 1 | OXALIPLATIN INJECTION, USP | Sourceable in Canada |
| PFIZER CANADA ULC | 1 | 1 | OXALIPLATIN | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 1 | 1 | OXALIPLATIN INJECTION | Sourceable in Canada |
| ACTAVIS PHARMA COMPANY | 3 | 0 | ACT OXALIPLATIN | No marketed DIN |
| HOSPIRA HEALTHCARE ULC | 3 | 0 | OXALIPLATIN FOR INJECTION, OXALIPLATIN INJECTION | No marketed DIN |
| SANOFI-AVENTIS CANADA INC | 3 | 0 | ELOXATIN | No marketed DIN |
| AURO PHARMA INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| EUGIA PHARMA INC. | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| GENERIC MEDICAL PARTNERS INC | 1 | 0 | OXALIPLATIN INJECTION | No marketed DIN |
| PHARMASCIENCE INC | 1 | 0 | PMS-OXALIPLATIN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 5 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | 50 mg / 10 mL, 100 mg / 20 mL, 200 mg / 40 mL |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Oxaliplatin |
|---|---|
| ATC code | L01XA03 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02458403 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2458403 |
| Brand name | OXALIPLATIN INJECTION, USP |
| Generic / active ingredient | OXALIPLATIN : 5 MG |
| Market authorization holder | DR REDDY'S LABORATORIES LTD |
| Health Canada schedule | Prescription |
| ATC code | L01XA03 |
| ATC anatomical main group | L — Antineoplastic and immunomodulating agents |
| ATC therapeutic subgroup | L01XA |
| Current status | MARKETED |
| Status date | 13-Jul-2022 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Oxaliplatin in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by DR REDDY'S LABORATORIES LTD, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
5 of 22 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| OXALIPLATIN | 5 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02444763 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02435071 |
| OXALIPLATIN INJECTION | 5 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | 02436957 |
| OXALIPLATIN INJECTION, USP | 5 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02457423 |
| ACT OXALIPLATIN | 50 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430525 |
| ACT OXALIPLATIN | 100 MG | POWDER FOR SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED PRE MARKET | 02430533 |
| ACT OXALIPLATIN | 5 MG | SOLUTION | ACTAVIS PHARMA COMPANY | CANCELLED POST MARKET | 02432617 |
| ELOXATIN | 5 MG | SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296284 |
| ELOXATIN | 50 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296268 |
| ELOXATIN | 100 MG | POWDER FOR SOLUTION | SANOFI-AVENTIS CANADA INC | CANCELLED POST MARKET | 02296276 |
2 · Same class — other molecules in ATC L01XA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Oxaliplatin | ACT OXALIPLATIN · ELOXATIN · OXALIPLATIN · OXALIPLATIN FOR INJECTION · +6 more | 22 | 5 | Yes |
| Cisplatin | CISPLATIN INJ 0.5MG/ML · CISPLATIN INJ 1MG/ML · CISPLATIN INJECTION · CISPLATIN INJECTION BP · +4 more | 13 | 4 | Yes |
| Carboplatin | CARBOPLATIN INJECTION · CARBOPLATIN INJECTION BP · CARBOPLATIN INJECTION LIQ 10MG/ML · CARBOPLATIN INJECTION, BP · +2 more | 10 | 3 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC L01X
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| L01XX | Aflibercept · Altretamine · Amsacrine · Anagrelide · Arsenic Trioxide · +13 more | 48 | 23 |
| L01XG | Bortezomib · Carfilzomib · Ixazomib | 30 | 18 |
| L01XK | Niraparib · Niraparib And Abiraterone · Olaparib · Talazoparib | 12 | 7 |
| L01XL | Axicabtagene Ciloleucel · Brexucabtagene Autoleucel · Ciltacabtagene Autoleucel · Idecabtagene Vicleucel · Lifileucel · +2 more | 8 | 5 |
| L01XJ | Glasdegib · Sonidegib · Vismodegib | 4 | 4 |
| L01XD | Aminolevulinic Acid · Methyl Aminolevulinate · Porfimer Sodium | 5 | 3 |
| L01XM | Enasidenib · Vorasidenib | 4 | 2 |
| L01XF | Tretinoin | 2 | 2 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is OXALIPLATIN INJECTION, USP called?
The same molecule, Oxaliplatin, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Oxaliplatin Accord | Latin | Australia, Czechia |
| OXALIPLATIN KALCEKS | Latin | Czechia |
| Xaliptine | Latin | Saudi Arabia |
| OXALIPLATIN | Latin | Lebanon |
| OXALIPLATIN BAXTER | Latin | Australia |
| OXALIPLATIN KABI | Latin | Czechia |
| OXALIPLATIN TEVA | Latin | Czechia |
| OXALIPLATIN AGMED | Latin | Czechia |
| OXALIPLATIN EBEWE | Latin | Bahrain |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.